Table 2 IC50 Values (±SEM) for chemical treatments in LPM differentiation assay.

From: Thalidomide Inhibits Human iPSC Mesendoderm Differentiation by Modulating CRBN-dependent Degradation of SALL4

hiPSC Line

Gibco hiPSCs

XCL-1 hiPSC

Clone

N/A

CRBN Mock

CRBN KO/KI

SALL4 Mock

SALL4G416A

Thalidomide

0.31 ± 0.19

0.56 ± 0.45

>50

0.69 ± 0.50

>50

Pomalidomide

0.01 ± 0.01

0.02 ± 0.01

>50

0.09 ± 0.09

>50

Lenalidomide

0.16 ± 0.08

0.09 ± 0.08

>50

0.84 ± 1.2

>50

atRA

0.82 ± 0.78

2.70 ± 2.0

8.17 ± 5.1

2.94 ± 1.2

9.10 ± 5.9

SB431542

2.76 ± 5.58

0.65 ± 0.18

0.79 ± 0.4

0.63 ± 0.17

0.51 ± 0.10

Back to article page